<DOC>
	<DOCNO>NCT03037411</DOCNO>
	<brief_summary>The REGAL study European , prospective , multi-center Post-Market Clinical Follow-up ( PMCF ) trial provide additional data include health economics data support use ELUVIA stent treatment lesion locate femoropopliteal artery .</brief_summary>
	<brief_title>A Real World Evaluation ELUVIA Stent Subjects With Lesions Located Femoropopliteal Arteries</brief_title>
	<detailed_description>A European , prospective , multi-center Post-Market Clinical Follow-up ( PMCF ) trial provide additional data include health economics data support use ELUVIA stent treatment lesion locate femoropopliteal artery . The objective study collect additional data include health economics data support use ELUVIA Drug-Eluting Vascular Stent System ( ELUVIA Stent ) treat Superficial Femoral Artery ( SFA ) and/or Proximal Popliteal Artery ( PPA ) lesion .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<criteria>1 . Subjects age 18 old 2 . Subject willing able provide write consent studyspecific test procedure perform agree attend followup visit 3 . De novo , restenotic ( ) occlude lesion native femoropopliteal artery , reference vessel diameter ( RVD ) range 4.06.0 mm , suitable endovascular treatment 1 . Subject pregnant planning become pregnant course study 2 . Life expectancy less 1 year ( define document life expectancy le 12 month due medical comorbid condition ( ) could limit subject 's ability participate clinical followup , limit subject 's compliance standard care followup , impact scientific integrity trial ) 3 . Known allergy ELUVIA stent system component , concomitant medication , contrast agent ( medically manage ) 4 . Subject enrol investigational study reach primary endpoint time enrollment clinically interfere current study assessment ( Note : study require extend followup product investigational , become commercially available since consider investigational study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Atherosclerosis</keyword>
	<keyword>Superficial Femoral Artery ( SFA )</keyword>
	<keyword>Proximal Popliteal Artery ( PPA )</keyword>
	<keyword>Stenting</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Health Economics</keyword>
</DOC>